Sign in
TerminatedEarly phase 1

A Pilot Study of Glutamine PET Imaging of Head and Neck Squamous Cell Carcinoma

Key facts

Who runs it
M.D. Anderson Cancer Center
Where
Houston, United StatesSee the site
Trial code
Status
Terminated
Phase
Early phase 1
People taking part
3 people enrolled
Started
14 Sept 2022
Ended
7 Mar 2025
Type of study
Interventional
Treatments tested
  • 18F-FSPG
  • 11C-Glutamine
Record updated
9 April 2025
Why it stopped
PI Request

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 10 criteriaShow less

Who can take part

  • ≥18 years of age
  • Pathologically or cytologically confirmed diagnosis of head and neck squamous cell carcinoma (HNSCC)
  • Documented results from (or scheduled to undergo) CT or MRI as a SOC procedure within 42 days prior to baseline investigational 11C-Gln PET/CT and 18F-FSPG PET/CT
  • Measurable disease by RECIST v1.1 defined as tumor lesions with a longest diameter ≥ 10 mm and/or malignant lymph nodes with a short axis diameter ≥ 15 mm
  • Ability to provide written informed consent in accordance with institutional policies
  • Non-English speaking subject will be included. Verbal Translation Preparative Sheet (VTPS) short form will be utilized in consent non-English speaking subject

Who cannot take part

  • Have an allergy to intravenous contrast
  • eGFR<30
  • Body weight ≥400 pounds or body habitus or disability that will not permit the imaging protocol to be performed
  • Pregnant or lactating females

Where in United States

  • M D Anderson Cancer CenterHouston, United States

About the trial

What the trial wants to find out

We propose a focused, prospective pilot clinical imaging trial to evaluate 11C-Gln PET/CT followed by 18F-FSPG PET/CT in 20 HNSCC patients. Imaging metrics that are common to PET (e.g. SUVmax, peak or mean) will be determined.

Read full original descriptionShow less

This study will also allow the acquisition of additional safety and biodistribution data, as, to date, only a limited number of patients have been evaluated with 11C-Gln as a direct PET imaging biomarker of Gln uptake. To date, no adverse side effects have been observed. We do not anticipate any toxicity since this tracer is a naturally-occurring essential amino acid in high abundance and is administered at sub-pharmacologic doses.

A long-term goal of these preliminary studies is to validate the utility of Gln PET imaging metrics for HNSCC and to expand this imaging technique to additional patients in prospective cohorts of patients with HNSCC.

The group in the trial

  • PET scanTreatment being tested

    PET scans: an 11C-Glutamine PET scan and an 18F-FSPG PET scan. A small tube (called an IV) will be placed in a vein in your arm through which you will receive the radioactive material for the PET scan(s).

    Treatment: 18F-FSPG and 11C-Glutamine

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
9 April 2025